Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study).

ABSTRACT:

Background

Lasmiditan, an oral 5-HT_1F receptor agonist, has been recently approved for acute migraine treatment. While its efficacy was confirmed in randomized clinical trials, scarce data is available regarding effectiveness and tolerability in the real-world setting.

Objectives

To evaluate lasmiditan effectiveness and tolerability in the real-world setting in 16 Italian headache centers.

Design

LasmiDitan as Acute migRaine Treatment (DART) study is a prospective, multicentric, observational study.

Methods

We enrolled 58 participants with migraine (84.5% females, age 49.0 (45.2-52.9) years, 24.1% with chronic migraine) reporting 9.4 (7.4-11.3) monthly migraine days. Participants were instructed to treat their migraine attacks with oral lasmiditan 50

SUBMITTER: Vaghi G 

PROVIDER: S-EPMC12722647 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature